As of November 14, 2026, Biocryst Pharmaceuticals Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 23, 2026 (Form 8-K, January 23, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Biocryst Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Biocryst Pharmaceuticals Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-23. Every row below is cited to the filing it comes from, and this page adds each new change as Biocryst Pharmaceuticals Inc files it.
Layoffs on record: 2 filings or notices, latest 2026-08-04 (layoff filings and notices).
Also on the record for Biocryst Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 6.2% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 6% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.9% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.16% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Deerfield Mgmt, L.P. | 6.81% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.3% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 7.3% of the class | 5%+ stakes | Source |
| September 19, 2025 | Stake report, Schedule 13G, by Deerfield Mgmt, L.P. | 5.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Biocryst Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Biocryst Pharmaceuticals Inc and the records around it.
Biocryst Pharmaceuticals Inc elsewhere on the record
- 5%+ stake filings Nov 2026
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: BridgeBio Oncology Therapeutics, Inc. (Nov 2026), Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Evommune, Inc. (Nov 2026), Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026)
- STATE STREET CORPORATION also filed stake reports on 378 other companies: 4D MOLECULAR THERAPEUTICS INC (Nov 2026), ACADIA PHARMACEUTICALS INC (Nov 2026), ALBEMARLE CORP (Nov 2026)
Watch Biocryst Pharmaceuticals Inc
Get an email when Biocryst Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biocryst Pharmaceuticals Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Biocryst Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biocryst Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-23 | Reported | not named in the filing | 8-K/A, 2026-01-23 |
New leaders reset buying decisions — get the Full Report on Biocryst Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Biocryst Pharmaceuticals Inc, with the record behind each one.
Find candidates like senior executive at Biocryst Pharmaceuticals IncEvery change, in the filing's words
Reported
On October 14, 2025, BioCryst filed a Current Report on Form 8-K (the " Initial 8-K ") regarding the appointment of Jill C. Milne, Ph.D. to its board of directors (the " Board "), subject to certain conditions specified in the Merger Agreement.
- On January 23, 2026 (the "Closing Date"), BioCryst Pharmaceuticals, Inc., a Delaware corporation ("BioCryst") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the "Merger Agreement"), by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst ("Merger Sub") and Astria Therapeutics, Inc., a Delaware corporation ("Astria").
- On the Closing Date, Merger Sub merged with and into Astria (the "Merger"), with Astria surviving the Merger as a wholly owned subsidiary of BioCryst.
- On the Closing Date, such conditions were satisfied and Dr. Milne's appointment to the Board became effective.
- This Amendment No. 1 to the Initial 8-K is being filed to report that on January 20, 2026, the Board appointed Dr. Milne as a member of its Compensation and Science Committees, effective as of the Closing Date.
Tools for this story
Each opens in a new tab, filled in for Biocryst Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
